OOIR: Observatory of International Research

Papers

(The TQCC of Best Practice & Research Clinical Haematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Contemporary and future strategies in polycythemia vera	69
The role of randomized controlled trials, registries, observational databases in evaluating new interventions	27
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation	25
Coagulopathy in COVID-19 and anticoagulation clinical trials	25
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL	22
Endpoint selection and evaluation in hematology studies	22
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)	21
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program	19
Editorial Board	19
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes	19
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances	19
The presentation of results from studies in clinical haematology	16
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms	14
Take a spin: Apheresis in the care of adult leukaemia patients	14
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma	11
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults	11
Vaccine-induced immune thrombotic thrombocytopenia	11
Targeted cellular therapy for treatment of relapsed or refractory leukemia	10
Principles of cost-effectiveness studies and their use in haematology	10
Blood coagulation and cancer genes	10
Accelerated and blast phase myeloproliferative neoplasms	10
Creating a GMP cell processing program: A focus on quality and regulation	10
The international cooperative Gaucher group (ICCG) Gaucher registry	9
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”	9
What should be done and what should be avoided when comparing two treatments?	9

Dysregulation of Protein S in COVID-19	8
Editorial Board	8
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma	8
Cancer associated thrombosis in pediatric patients	8
Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025]	7
Addressing symptom burden in myeloproliferative neoplasms	7
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration	7
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?	7
Anti-GM-CSF autoantibodies in myeloid leukemias	7
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders	7
The role of registries in hematological disorders	7
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation	7
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma	7
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies	6
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment	6
Challenges in anticoagulation for patients with brain tumors	6
Handling missing covariate data in clinical studies in haematology	6
Thrombosis and bleeding in hematological malignancy	6
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation	5
Recent progress in acute leukemia and myelodysplasia	5
A reflection on Arnold Caplan, the father of MSC	5
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia	5
Editorial Board / Aims & Scope	5
CAR assembly line: Taking CAR T-cell manufacturing to the next level	5
Cytokines in hematopoietic cell transplantation and related cellular therapies	5